E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
children from 5 to 18 years with grass pollen induced rhinoconjunctivitis with/without controlled asthma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054928 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the 3 years efficacy, tolerability, safety of specific immunotherapy with Grazax compared to placebo on the top of rescue allergic symptomatic drugs in children with grass pollen induced rhinoconjunctivitis with or without controlled or partly controlled asthma. |
|
E.2.2 | Secondary objectives of the trial |
total number of days with severe symptoms during the 1, 2 and 3rd years of treatment (pollen season 2010, 2011 and 2012) -the average rhinoconjunctivitis symptom score and medication score in the entire grass pollen season during 1, 2 and 3 years - the average rhinoconjunctivitis symptoms in the peak grass pollen season by VAS during 1,2 and 3 years of treatment -recording of all adverse events and all SAE -the average asthma medication symptom score in the entire grass pollen season and in the peak pollen season. A total of 4 asthma symptoms should be measured on a scale from 0 to 3. -findings from physical examination, vital signs and FEV1 as well as monitoring of hematology, blood chemistry and urine values. -Profilin sensitization with SPT with Palm profiling |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Boys and girls 5-18 years of age 2. Written informed consent obtained from parents/guardians and from subjects if the level of intellectual maturity makes it appropriate. Assent will be obtained from subjects turning 18 during the trial. 3. A clinical history of grass pollen induced allergic rhinoconjunctivitis with controlled or partly controlled asthma having received treatment during the previous grass pollen season. 4. Positive Skin Prick Test (SPT) response (wheal diameter > 3 mm) to Phleum pratense 5. Positive specific IgE against Phleum pratense( >IgE Class 2 ) 6. Female subject who are fertile, must have a negative pregnancy test. In case of female subjects adequate methods to avoid pregnancy should be used. (in case of pregnancy the subject will stop to take study medication and will be followed until delivery) 7. Subject and parent/guardian willing and able to comply with trial protocol regimens. |
|
E.4 | Principal exclusion criteria |
1. A clinical history of symptomatic seasonal allergic rhinitis and asthma, having received regular medication, due to another allergen during-or potentially overlapping- the grass pollen season 2. A clinical history of perennial allergic rhinitis and asthma having received regular medication due to an allergen to which the subject is regular exposed. 3. A clinical history of chronic sinusitis during the last 2 years. 4. A clinical history of severe asthma and/or a FEV1 <80% 5. Any clinical relevant chronic disease such as hepatic or renal insufficiency, immunological diseases (Rheumatoid arthritis, lymphoma ect) 6. Current severe atopic dermatitis 7. Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years 8. History of anaphylaxis 9. Chronic urticaria and angioedema. 10. Immunosuppressive treatments (cyclosporine and other immunomodulating drugs such as metothrexate, azathioprine ) (except for steroids for allergic symptoms) 11. History of allergy, hypersensitivity or intolerance to investigational medicinal product ( except for Phleum pratense) or rescue medications 12. Unlike to be able to complete the trial, for any reason, or likely to move, or travel for extended periods of time during the trial period. 13. Being immediate family of the Investigator or trial staff, defined as the investigators/staffs child or grandchild. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the comparison between the two groups of the total number of days with severe symptoms during the pollen season after 3 years of treatment (pollen season 2012). A total of 6 rhinoconjunctivitis symptoms should be measured on a scale from 0-3 (patients diary).According to Durham et al, (EAACI 2008) and Bufe et al (JACI 2009) using therefore a symptom score (SS) with a scale ranging from 0 to 18, (6 items) a day with severe symptom will be defined as a day with a SS ≥10, despite the use of rescue medications. SS would be measured with a patient diary card during the entire pollen season. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |